Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
- 200+ team members in Tübingen and Munich, Germany and Houston, Texas
- 200+ targets covering major solid and liquid tumors
- 2 proprietary technology platforms, XPRESIDENT® and XCEPTOR™
- 9 proprietary drug discovery programs; 4 of which are in clinical development
- Multiple partnered programs
Since its foundation in 2000 as a spin out from H.G. Rammensee’s laboratory at University of Tübingen, Germany, Immatics has revolutionized the identification of tumor-associated pHLA targets, which are recognized by T cells. Identifying true cancer targets that are presented on tumor tissue but not on healthy cells and the subsequent discovery, selection, and engineering of a therapeutic TCR are central to Immatics‘ mission: Delivering the power of T cells to cancer patients and advance the next wave in cancer immunotherapy.
In 2015, Immatics and MD Anderson Cancer Center launched Immatics US, Inc. in Houston, Texas as a joint venture to develop transformative Adoptive Cell Therapies.
Immatics has an experienced global leadership team across Europe and the U.S. and is supported by a thriving, talented and knowledgeable team with diverse backgrounds and complementary skill sets.